Ninety days transplant free survival with high volume plasma exchange in Wilson disease presenting as acute liver failure

• Published in: Journal of clinical apheresis Vol. 36; no. 1; pp. 109 - 117
• Main Authors: Pawaria, Arti, Sood, Vikrant, Lal, Bikrant Bihari, Khanna, Rajeev, Bajpai, Meenu, Alam, Seema
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.02.2021; Wiley Subscription Services, Inc
• Subjects: acute liver failure; Apheresis; Liver diseases; liver transplantation; Liver transplants; Plasma; plasma exchange; Survival analysis; transplant free survival; Wilson disease; transplant free survival; Wilson disease; plasma exchange; acute liver failure; liver transplantation
• ISSN: 0733-2459; 1098-1101; 1098-1101
• DOI: 10.1002/jca.21848

Objective To study the efficacy and safety of high volume plasma exchange (HVPE) in Wilson disease presenting as acute liver failure (WD‐ALF). Methods An analysis of prospectively collected data of consecutively admitted WD‐ALF cases was done and patients were divided into two groups: (i) high volume plasma exchange (HVPE) group‐ who received HVPE + standard medical therapy (SMT), and (ii) SMT group‐ received only SMT. Outcome measure was transplant free survival (TFS) at 90 days post enrollment, change in biochemical, hemodynamic parameters & incidence of organ dysfunction in HVPE as compared to SMT group, and HVPE related complications. Results Out of the total 43 cases of WD‐ALF reported in the study period, 37 were enrolled (median age 9 years, 62.2% males). All biochemical parameters and prognostic indices except blood ammonia and serum creatinine improved significantly at 72 to 96 hours after enrollment in the HVPE group. Overall, TFS at 90 days was present in 9/19 (47.3%) in HVPE group vs 3/18 (16.6%) in the SMT group (OR 2.84, 95% CI 0.91‐8.8, P = .049). Kaplan Meier survival analysis revealed that HVPE group had significantly higher cumulative survival as per the Log Rank test (P = .027); median days of survival was 38 days (IQR 12‐63) in HVPE group vs 14 (IQR 5‐22) days in SMT group. Conclusions The present study indicates that in children with WD‐ALF, HVPE not only acts as a bridging therapy to LT but may also improve proportion of the cases with TFS.